A Viral Protein Antagonist for Both AID and APOBEC3.

Abstract readReview

In one paragraph

Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jaquelin P DudleyDepartment of Molecular Biosciences and LaMontagne Center for Infectious Disease, The University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0002-1581-1098

Funding

National Institute of Allergy and Infectious Diseases R01AI131660

6 · The paper itself

Abstract

The APOBEC family of cytidine deaminases is part of the innate immune response to infections by multiple RNA- and DNA-containing viruses. Since the activity of these enzymes, typically APOBEC3, often involves mutations that inhibit or block viral replication, viruses have evolved antagonists that limit APOBEC function. The retrovirus mouse mammary tumor virus (MMTV) encodes an APOBEC antagonist, Rem. Surprisingly, Rem appears to inhibit APOBEC3 through proteasomal degradation of a different APOBEC enzyme, AID.

Indexed as

Cytidine DeaminaseMammary Tumor Virus, MouseViral ProteinsAICDA (Activation-Induced Cytidine Deaminase)AnimalsHumansImmunity, InnateMiceVirus ReplicationAICDA (Activation-Induced Cytidine Deaminase)Cytidine DeaminaseViral Proteinsactivation-induced cytidine deaminaseAPOBEC antagonistERADinnate immunityRemviral DNA mutagenesis

Identifiers

PMID42043189

DOI10.3390/v18040399

PMCPMC13120120

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.